NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report issued on Thursday. The firm set a “hold” rating on the stock.

NovaBay Pharmaceuticals Trading Up 5.7 %

NYSE:NBY opened at $0.50 on Thursday. NovaBay Pharmaceuticals has a 12 month low of $0.36 and a 12 month high of $9.08. The firm’s 50 day moving average is $0.61 and its 200 day moving average is $0.63. The stock has a market capitalization of $2.91 million, a PE ratio of -0.01 and a beta of 0.90.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.